Molecular alterations underlying eosinophilic and mast cell malignancies

Discovery Medicine

Volumn 12, Issue 67, 2011, Pages 481-493

  Sadrzadeh, Hossein ^a   Abdel Wahab, Omar ^b   Fathi, Amir T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; MASITINIB; MIDOSTAURIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL (TOPIC); EOSINOPHILIC LEUKEMIA; FUSION GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPEREOSINOPHILIA; KARYOTYPE; MAST CELL LEUKEMIA; MASTOCYTOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; SYSTEMIC MASTOCYTOSIS; URTICARIA PIGMENTOSA; ANIMAL; CELL CLONE; DRUG EFFECT; EOSINOPHIL; EOSINOPHILIA; GENETICS; MAST CELL; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; CLONE CELLS; EOSINOPHILIA; EOSINOPHILS; HUMANS; MAST CELLS; MASTOCYTOSIS; PROTEIN KINASE INHIBITORS;

EID: 84865829659     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (119)

1. Abe A, Emi N, Tanimoto M, Terasaki H, Marunouchi T, Saito H. Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 90(11):4271-4277, 1997.
2. Abruzzo LV, Jaffe ES, Cotelingam JD, Whang-Peng J, Del Duca V, Jr, Medeiros LJ. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol 16(3):236-245, 1992.
3. Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 38(11):869-873, 2008.
4. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 28(2):140-147, 2000.
5. Albano F, Anelli L, Zagaria A, Lonoce A, La Starza R, Liso V, Rocchi M, Specchia G. Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia. Leukemia Res 32(2):347-351, 2008.
6. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347(7):481-487, 2002.
7. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, De Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, AstolfiC, Pane F, Saglio G, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9):1173-1179, 2007.
8. Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL, Bennett KL, Samorapoompichit P, Lee FY, Pickl WF, Esterbauer H, Sillaber C, Superti-Furga G, Valent P. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 36(10):1244-1253, 2008.
9. Belloni E, Trubia M, Gasparini P, Micucci C, Tapinassi C, Confalonieri S, Nuciforo P, Martino B, Lo-Coco F, Pelicci PG, Di Fiore PP. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer 42(3):320-325, 2005.
10. Bhatti FA, Hussain I, Ali MZ. Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia-case report and review of literature. J Hematol Oncol 2:26, 2009.
11. Bigoni R, Cuneo A, Roberti MG, Milani R, Bardi A, Cavazzini F, Minotto C, Castoldi G. Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome. Haematologica 85(5):486-491, 2000.
12. Bitran JD, Rowley JD, Plapp F, Golomb HM, Ultmann JE. Chromosomal aneuploidy in a patient with hypereosinophilic syndrome. Evidence for a malignant disease. Am J Med 63(6):1010-1014, 1977.
13. Brigaudeau C, Liozon E, Bernard P, Trimoreau F, Bordessoule D, Praloran V. Deletion of chromosome 20q associated with hypereosinophilic syndrome. A report of two cases. Cancer Genet Cytogenet 87(1):82-84, 1996.
14. Brito-Babapulle F. Patients with eosinophilic fasciitis should have a bone marrow examination to identify myelodysplasia. Br J Dermatol 137(2):316-317, 1997.
15. Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 111(6):1227-1231, 1998.
16. Cabrol C. Chromosomal anomaly in eosinophilic leukemia. N Engl J Med 301(8):439, 1979.
17. Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Galinsky I, Huntly B, Cohen PS, Meyer T, Fabbro D, Roesel J, Banerji L, Griffin JD, Xiao S, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 101(40):14479-14484, 2004.
18. Chusid MJ, Dale DC, West BC, WolffSM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 54(1):1-27, 1975.
19. Cools J, Deangelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201-1214, 2003.
20. Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G, Minervini MM, Stewart J, Reiter A, Cross NC. Two novel imatinibresponsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 138(1):77-81, 2007.
21. Da Silva MA, Heerema N, Schwenk GR, Jr, Hoffman R. Evidence for the clonal nature of hypereosinophilic syndrome. Cancer Genet Cytogenet 32(1):109-115, 1988.
22. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, Gardembas M, Goldman JM, Grand F, Hughes G, Huguet F, Lavender L, Mcarthur GA, Mahon FX, Massimini G, Melo J, Rousselot P, Russell-Jones RJ, Seymour JF, Smith G, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109(1):61-64, 2007.
23. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 360(22):2289-2301, 2009.
24. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, Koduru P, Brody JP, Hawson G, Rodwell R, Doody ML, Carnicero F, Reiter A, Goldman JM, Melo JV, Cross NC. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 98(13):3778-3783, 2001.
25. Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol 3(4):448-457, 2010.
26. Duell T, Mittermuller J, Schmetzer HM, Kolb HJ, Wilmanns W. Chronic myeloid leukemia associated hypereosinophilic syndrome with a clonal t(4;7)(q11;q32). Cancer Genet Cytogenet 94(2):91-94, 1997.
27. Ellman L, Hammond D, Atkins L. Eosinophilia, chloromas and a chromosome abnormality in a patient with a myeloproliferative syndrome. Cancer 43(6):2410-2413, 1979.
28. Erben P, Gosenca D, Muller MC, Reinhard J, Score J, Del Valle F, Walz C, Mix J, Metzgeroth G, Ernst T, Haferlach C, Cross NC, Hochhaus A, Reiter A. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 95(5):738-744, 2010.
29. Ferrao PT, Gonda TJ, Ashman LK. Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leukemia Res 27(6):547-555, 2003.
30. Forghieri F, Morselli M, Potenza L, Maccaferri M, Pedrazzi L, Paolini A, Bonacorsi G, Artusi T, Giacobbi F, Corradini G, Barozzi P, Zucchini P, Marasca R, Narni F, Crescenzi B, Mecucci C, Falini B, Torelli G, Luppi M. Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma. Eur J Haematol 86(4):352-355, 2011.
31. Forrest DL, Horsman DE, Jensen CL, Berry BR, Dalal BI, Barnett MJ, Nantel SH. Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization. Cancer Genet Cytogenet 107(1):65-68, 1998.
32. Fritsche-Polanz R, Fritz M, Huber A, Sotlar K, Sperr WR, Mannhalter C, Fodinger M, Valent P. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 4(4):335-346, 2010.
33. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, Fodinger M. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 113(2):357-364, 2001.
34. Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, Satoh Y, Shibayama H, Tanaka H, Iwama A, Kanakura Y. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 284(12):7719-7732, 2009.
35. Gallagher G, Horsman DE, Tsang P, Forrest DL. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders. Cancer Genet Cytogenet 181(1):46-51, 2008.
36. Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hormann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 118(7):1885-1898, 2011.
37. Goffman TE, Mulvihill JJ, Carney DN, Triche TJ, Whang-Peng J. Fatal hypereosinophilia with chromosome 15q-in a patient with multiple primary and familial neoplasms. Cancer Genet Cytogenet 8(3):197-202, 1983.
38. Goh KO, Ho FS, Tso SC, Ma J. Is hypereosinophilic syndrome a malignant disease? Cancer 55(10):2395-2399, 1985.
39. Goldman JM, Najfeld V, Th'ng KH. Agar culture and chromosome analysis of eosinophilic leukaemia. J Clin Pathol 28(12):956-961, 1975.
40. Gotlib J. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Curr Opin Hematol 17(2):117-124, 2010.
41. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106(8):2865-2870, 2005.
42. Gotlib J, Cools J, Malone JM, 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103(8):2879-2891, 2004.
43. Grand FH, Burgstaller S, Kuhr T, Baxter EJ, Webersinke G, Thaler J, Chase AJ, Cross NC. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 64(20):7216-7219, 2004.
44. Guasch G, Mack GJ, Popovici C, Dastugue N, Birnbaum D, Rattner JB, Pebusque MJ. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 95(5):1788-1796, 2000.
45. Guasch G, Popovici C, Mugneret F, Chaffanet M, Pontarotti P, Birnbaum D, Pebusque MJ. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood 101(1):286-288, 2003.
46. Hild F, Fonatsch C. Cytogenetic peculiarities in chronic myelogenous leukemia. Cancer Genet Cytogenet 47(2):197-217, 1990.
47. Hogge DE, Misawa S, Parsa NZ, Pollak A, Testa JR. Abnormalities of chromosome 16 in association with acute myelomonocytic leukemia and dysplastic bone marrow eosinophils. J Clin Oncol 2(6):550-557, 1984.
48. Humphrey MJ, Hutter, Tom WW. Hypereosinophilia in a monosomy 7 myeloproliferative disorder in childhood. Am J Hematol 11(1):107-110, 1981.
49. Irani AM, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, Zsebo KM, Schwartz LB. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80(12):3009-3021, 1992.
50. Jain N, Cortes J, Quintas-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leukemia Res 33(6):837-839, 2009.
51. Keane C, Henden A, Mills T, Wood P. Myeloid and lymphoid neoplasm with FGFR1 abnormality. Br J Haematol 145(4):440, 2009.
52. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61(23):2924-2931, 2004.
53. Kobayashi H, Kitano K, Shimodaira S, Ishida F, Saito H, Sonoyama M, Enokihara H, Furuta S. Eosinophilia in myelodysplastic syndrome with a (12;21)(q23;q22) translocation. Cancer Genet Cytogenet 68(2):95-98, 1993.
54. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, Kaeda J, Cwynarski K, Goldman JM, Cross NC. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 60(13):3592-3598, 2000.
55. La Starza R, Rosati R, Roti G, Gorello P, Bardi A, Crescenzi B, Pierini V, Calabrese O, Baens M, Folens C, Cools J, Marynen P, Martelli MF, Mecucci C, Cuneo A. A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome. Leukemia 21(4):830-833, 2007.
56. La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B, Martelli M, Flandrin G, Pelicci PG, Mecucci C. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 87(8):789-794, 2002.
57. Lepretre S, Jardin F, Buchonnet G, Lenain P, Stamatoullas A, Kupfer I, Courville P, Callat MP, Contentin N, Bastard C, Tilly H. Eosinophilic leukemia associated with t(2;5)(p23;q31). Cancer Genet Cytogenet 133(2):164-167, 2002.
58. Lishner M, Confino-Cohen R, Mekori YA, Feigin M, Manor Y, Goldberg A, Ravid M, Amiel A. Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis. J Allergy Clin Immunol 98(1):199-204, 1996.
59. Longley BJ, Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96(4):1609-1614, 1999.
60. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12(3):312-314, 1996.
61. Lonnqvist B, Gahrton G, Eriksson P, Friberg K, Zech L. Isochromosome 17 in a patient with a myeloproliferative disorders terminating in eosinophilic leukemia. Acta Med Scand 206(4):321-325, 1979.
62. MacDonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107(2):101-107, 2002.
63. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 98(8):2518-2525, 2001.
64. Malbrain ML, Van Den Bergh H, Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 92(1):176-183, 1996.
65. Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 120(3):680-687, 2007.
66. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Muller MC, Beneke H, Muller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Muller-Hermelink K, Hodges E, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 21(6):1183-1188, 2007.
67. Michel G, Thuret I, Capodano AM, Scheiner C, Guitard AM, Mozziconacci MJ, Fossat C, Perrimond H. Myelofibrosis in a child suffering from a hypereosinophilic syndrome with trisomy 8: response to corticotherapy. Med Ped Oncol 19(1):62-65, 1991.
68. Mitelman F, Panani A, Brandt L. Isochromosome 17 in a case of eosinophilic leukaemia. An abnormality common to eosinophilic and neutrophilic cells. Scand J Haematol 14(4):308-312, 1975.
69. Mitter NS, Weiskopf RW. Unusual chromosome 7 aberrations in a case of eosinophilic myeloproliferative syndrome. Cancer Genet Cytogenet 26(2):209-212, 1987.
70. Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F, Maserati E, Pasquali F, Panarello C. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res 64(8):2649-2651, 2004.
71. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92(23):10560-10564, 1995.
72. Needleman SW, Mane SM, Gutheil JC, Kapil V, Heyman MR, Testa JR. Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol 4(3):149-155, 1990.
73. Oliver JW, Deol I, Morgan DL, Tonk VS. Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet 107(2):111-117, 1998.
74. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102(9):3093-3096, 2003.
75. Park TS, Song J, Kim JS, Yang WI, Song S, Kim SJ, Suh B, Choi JR. 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality. Cancer Genet Cytogenet 181(2):93-99, 2008.
76. Parreira L, Tavares De Castro J, Hibbin JA, Marsh JC, Marcus RE, Babapulle VB, Spry CJ, Goldman JM, Catovsky D. Chromosome and cell culture studies in eosinophilic leukaemia. Br J Haematol 62(4):659-669, 1986.
77. Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, Ketterling RP, Tefferi A. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol 85(4):238-242, 2010.
78. Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmerini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 85(12):921-925, 2010.
79. Popovici C, Adelaide J, OllendorffV, Chaffanet M, Guasch G, Jacrot M, Leroux D, Birnbaum D, Pebusque MJ. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci U S A 95(10):5712-5717, 1998.
80. Popovici C, Zhang B, Gregoire MJ, Jonveaux P, Lafage-PochitaloffM, Birnbaum D, Pebusque MJ. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 93(4):1381-1389, 1999.
81. Presti C, Ryan T, Armstrong WF. Two-dimensional and Doppler echocardiographic findings in hypereosinophilic syndrome. Am Heart J 114(1 Pt 1):172-175, 1987.
82. Pullarkat ST, Pullarkat V, Kroft SH, Wilson CS, Ahsanuddin AN, Mann KP, Thein M, Grody WW, Brynes RK. Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. J Hematopathol 2(1):27-33, 2009.
83. Pullarkat VA, Bueso-Ramos C, Lai R, Kroft S, Wilson CS, Pullarkat ST, Bu X, Thein M, Lee M, Brynes RK. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 73(1):12-17, 2003.
84. Quiquandon I, Claisse JF, Capiod JC, Delobel J, Prin L. alpha-Interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood 85(8):2284-2285, 1995.
85. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC, Goncalves C, Hernandez JM, Jennings BA, Goldman JM, Cross NC. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 92(5):1735-1742, 1998.
86. Ribeiro I, Carvalho IR, Fontes M, Lima F, Matos R, Anderson BA, Uva LS. Eosinophilic leukaemia with trisomy 8 and double gammopathy. J Clin Pathol 46(7):672-673, 1993.
87. Rosati R, La Starza R, Luciano L, Gorello P, Matteucci C, Pierini V, Romoli S, Crescenzi B, Rotoli B, Martelli MF, Pane F, Mecucci C. TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukemia 20(9):1623-1624, 2006.
88. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91(12):4419-4426, 1998.
89. Sanada I, Asou N, Kojima S, Kawano F, Shido T, Takatsuki K. Acute myelogenous leukemia (FAB M1) associated with t(5;16) and eosinophilia. Report of an additional case. Cancer Genet Cytogenet 43(1):139-141, 1989.
90. Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, Teodosio C, Jara-Acevedo M, Pedreira CE, Matito A, Morgado JM, Sanchez ML, Mollejo M, Gonzalez-De-Olano D, Orfao A, Escribano L. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 24(9):1157-1168, 2011.
91. Sato H, Danbara M, Tamura M, Morita M. Eosinophilic leukaemia with a t(2;5)(p23;q35) translocation. Br J Haematol 87(2):404-406, 1994.
92. Schoffski P, Ganser A, Pascheberg U, Busche G, Gaede B, Hertenstein B. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol 79(2):95-98, 2000.
93. Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, Williams IR, Lastarza R, Crescenzi B, Sternberg DW, Andreasson P, Schiavo R, Siena S, Mecucci C, Gilliland DG. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 97(12):3910-3918, 2001.
94. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC. Identification of a novel imatinib responsive KIF5BPDGFRA fusion gene following screening for PDGFRA overex-pression in patients with hypereosinophilia. Leukemia 20(5):827-832, 2006.
95. Shanske AL, Kalman A, Grunwald H. A myeloproliferative disorder with eosinophilia associated with a unique translocation (3;5). Br J Haematol 95(3):524-526, 1996.
96. Smedley D, Hamoudi R, Clark J, Warren W, Abdul-Rauf M, Somers G, Venter D, Fagan K, Cooper C, Shipley J. The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet 7(4):637-642, 1998.
97. Stover EH, Chen J, Lee BH, Cools J, Mcdowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, Fabbro D, Manley PW, Griffin JD, Gilliland DG. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106(9):3206-3213, 2005.
98. Suzuki S, Chiba K, Toyoshima N, Kurosawa M, Hashino S, Musashi M, Asaka M. Chronic eosinophilic leukemia with t(6;11)(q27;q23) translocation. Ann Hematol 80(9):553-556, 2001.
99. Swolin B, Rodjer S, Roupe G. Cytogenetic studies and in vitro colony growth in patients with mastocytosis. Blood 70(6):1928-1932, 1987.
100. Tashiro H, Shirasaki R, Noguchi M, Gotoh M, Kawasugi K, Shirafuji N. Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. Int J Hematol 83(5):433-438, 2006.
101. Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc 80(1):75-83, 2005.
102. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 85(2):158-164, 2010.
103. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23(5):900-904, 2009.
104. Traina F, Jankowska A, Makishima H, Hsieh FH, Han Y, O'keefe C, Sugimoto Y, Mohan SR, Szpurka H, Prince C, Guinta K, Sekeres MA, Kalaycio M, Lichtin AE, Advani AS, Copelan E, Sobecks R, Maciejewski JP, Tiu RV. New TET2, ASXL1 and CBL mutations have poor prognostic impact in systemic mastocytosis and related disorders. Blood (ASH Annual Meeting Abstracts) 116(21), 2010.
105. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today 15(3):111-114, 1994.
106. Valent P, Akin C, Sperr WR, Mayerhofer M, Fodinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 46(1):35-48, 2005.
107. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintas-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33(11):1481-1484, 2009.
108. Verstovsek S, Giles FJ, Quintas-Cardama A, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A, Kantarjian H. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 30(12):1499-1505, 2006.
109. Verstovsek S, Tefferi A, Cortes J, O'brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14(12):3906-3915, 2008.
110. Viniou N, Yataganas X, Abazis D, Paterakis G, Vavourakis S, Stamatopoulos K, Matzourani M, Loukopoulos D, Pangalos C. Hypereosinophilia associated with monosomy 7. Cancer Genet Cytogenet 80(1):68-71, 1995.
111. Vizmanos JL, Novo FJ, Roman JP, Baxter EJ, Lahortiga I, Larrayoz MJ, Odero MD, Giraldo P, Calasanz MJ, Cross NC. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 64(8):2673-2676, 2004.
112. Walz C, Curtis C, Schnittger S, Schultheis B, Metzgeroth G, Schoch C, Lengfelder E, Erben P, Muller MC, Haferlach T, Hochhaus A, Hehlmann R, Cross NC, Reiter A. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 45(10):950-956, 2006.
113. Weide R, Rieder H, Mehraein Y, Wolf M, Kaiser U, Seifart U, Gorg C, Havemann K. Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. Br J Haematol 96(1):117-123, 1997.
114. Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, Aguiar RC. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 102(12):4187-4190, 2003.
115. Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, Fletcher JA. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 18(1):84-87, 1998.
116. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 100(2):661-665, 2002.
117. Yoo TJ, Orman SV, Patil SR, Dorminey C, Needleman S, Rajtora D, Graves N, Ackerman L, Taylor WW. Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome. Cancer Genet Cytogenet 11(4):389-384, 1984.
118. Yoshida C, Takeuchi M, Sadahira Y. A novel t(1;8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome. Br J Haematol, epub ahead of print, Aug. 18, 2011.
119. Zappulla JP, Dubreuil P, Desbois S, Letard S, Hamouda NB, Daeron M, Delsol G, Arock M, Liblau RS. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 202(12):1635-1641, 2005.